Open Angle Glaucoma With Elevated Intraocular Pressure Therapeutics
1. Lumigan patent expiration
Treatment: Lumigan is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; A method of lowering intraocular pressure; A...
LUMIGAN's oppositions filed in EPO
LUMIGAN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7851504 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Jun, 2027
(1 year, 5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5688819 | ABBVIE | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Aug, 2014
(11 years ago) | |
| US6403649 | ABBVIE | Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Sep, 2012
(13 years ago) | |
| US8017655 | ABBVIE | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Nov, 2012
(13 years ago) | |
| US9155716 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8299118 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US9241918 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8309605 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8338479 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8524777 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8586630 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8278353 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8933127 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8933120 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8772338 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 31, 2013 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 16 March, 2001
Dosage: SOLUTION/DROPS
How can I launch a generic of LUMIGAN before it's drug patent expiration?
More Information on Dosage
LUMIGAN family patents
2. Travatan patent expiration
Treatment: Method of stabilizing prostaglandin; Method for treating glaucoma and ocular hypertension
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5631287 | ALCON PHARMS LTD | Storage-stable prostaglandin compositions |
Dec, 2014
(11 years ago) | |
| US6011062 | ALCON PHARMS LTD | Storage-stable prostaglandin compositions |
Dec, 2014
(11 years ago) | |
| US5510383 | ALCON PHARMS LTD | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
Aug, 2013
(12 years ago) | |
| US5889052 | ALCON PHARMS LTD | Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension |
Dec, 2014
(11 years ago) | |
| US5849792 | ALCON PHARMS LTD | Storage-stable prostaglandin compositions |
Dec, 2014
(11 years ago) | |
Drugs and Companies using TRAVOPROST ingredient
Market Authorisation Date: 16 March, 2001
Dosage: SOLUTION/DROPS
How can I launch a generic of TRAVATAN before it's drug patent expiration?
More Information on Dosage
TRAVATAN family patents
3. Zioptan patent
expiration
Treatment: Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension
ZIOPTAN's oppositions filed in EPO
ZIOPTAN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5886035 | THEA PHARMA | Difluoroprostaglandin derivatives and their use |
Dec, 2017
(8 years ago) | |
| US10864159 | THEA PHARMA | Method and composition for treating ocular hypertension and glaucoma |
May, 2029
(3 years from now) | |
| US9999593 | THEA PHARMA | Method and composition for treating ocular hypertension and glaucoma |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 10, 2017 |
Drugs and Companies using TAFLUPROST ingredient
NCE-1 date: 11 February, 2016
Market Authorisation Date: 10 February, 2012
Dosage: SOLUTION/DROPS
How can I launch a generic of ZIOPTAN before it's drug patent expiration?
More Information on Dosage
ZIOPTAN family patents